I
slet transplantation has been shown to reverse type 1 diabetes mellitus (1, 2) . Although the rate of insulin independence after islet transplantation has improved significantly (1-3), long-term blood glucose control is still largely unachievable (1) . To improve the outcome of islet transplantation, one of the critical hurdles to overcome is the lack of a vascular network to support the newly transplanted islets. Endogenous native pancreatic islets are richly vascularized (4) . However, the process of isolating islets disrupts this specialized vasculature, thus threatening the survival of cells in the core of the islets (5) . Isolated islets are avascular, and the vascular network is regenerated within 14 days after transplantation (6) . During this time period, transplanted islets suffer from hypoxia. Approximately 60% of islets fail to engraft within 3 days after intraportal islet transplantation (7) , and hypoxia at the early posttransplant stages is considered a major reason for early islet graft loss.
Recently, bone marrow transplantation as a cell therapy for clinical disease has been increasingly studied. Mesenchymal stem cells (MSCs) derived from the bone marrow stroma constitute approximately 0.001% to 0.01% of the nucleated cells in the marrow (8) and can differentiate into various cell types including osteoblasts, adipocytes, cardiomyocytes, and endothelial cells (9) . It has been reported that MSCs can also differentiate into islet ␤ cells (10) , but other groups have reported little to no differentiation (11, 12) . Endothelial precursor cells (EPCs), a heterogeneous group of endothelial cell precursors originating in the hematopoietic compartment of bone marrow (8) , are capable of multipotent differentiation (13) and play an important role in angiogenesis of adult tissues (14) . Transplanted EPCs induce hypoxia inducible factor-1␣ under hypoxic conditions, which leads to upregulation of angiogenic factors, for example, vascular endothelial growth factor (VEGF) and promotes vascu-larization (14 -16) . EPCs also prevent ischemic tissues from undergoing apoptosis (17) . Moreover, EPCs themselves contribute to angiogenesis by migration to ischemic lesions and differentiation into endothelial cells (18) . Therefore, EPCs may have a beneficial effect in minimizing early graft loss after islet transplantation and improve vascularization.
This study evaluated the effect of bone marrow cotransplantation with islets on islet graft angiogenesis and function.
MATERIALS AND METHODS

Animals
BALB/c male mice (22-27 g, Charles River Laboratories. Inc., Boston, MA) were used as both donors and recipients. The mice were housed under pathogen-free conditions with a 12-hour light cycle and free access to food and water. All animal care and treatment procedures were approved by the Institutional Animal Care Use Committee.
Induction of Diabetes in Recipient Mice
Streptozotocin (200 mg/kg/mouse, Sigma-Aldrich, St. Louis, MO) was injected intraperitoneally, and blood glucose levels were measured by Accu-Chek Aviva glucose monitors (Roche, Indianapolis, IN). Recipient mice were used when the blood glucose level was greater than 19.3 mmol/L (350 mg/dL).
Islet Isolation
Murine islets were isolated by collagenase (collagenase V, Sigma-Aldrich) digestion, separated by Ficoll (Sigma-FIGURE 1. Blood glucose (A) and serum insulin (C) after islet and/or bone marrow transplantation up to postoperative day (POD) 28. Blood glucose was lowest in the isletϩbone marrow group and was decreased significantly compared with the bone marrow and sham groups. The same tendency was observed in serum insulin, which was highest in the isletϩbone marrow group. There was a significant increase in serum insulin in the isletϩ bone marrow group relative to the islet group at POD 28. The percentage of animals reaching normoglycemia (B) was higher in the isletϩbone marrow group (46.2%, 6/13) than in the islet group (25%, 3/12) (Pϭ0.32), and there were no normoglycemic mice in the bone marrow only or sham groups. There was also no significant difference between the islet (3.7Ϯ0.5 days) and isletϩbone marrow (5.8Ϯ1.7 days) groups in the days to normoglycemia (B). Glucose tolerance tests (GTT) at POD 7 (D), POD 14 (E), and POD 28 (F) revealed that there was a significant improvement in the isletϩ bone marrow group compared with the bone marrow and sham groups at POD 7. Statistical analysis was performed by two way repeated measurement analysis of variance (ANOVA), and significant difference was PϽ0.05.
Aldrich) discontinuous gradient and purified as described previously (19) . Collected islets were 133 to 200 m in size; islets greater than 267 m in size were rejected (20) . Based on previous results (21) , 200 islets were considered a marginal islet mass for restoring normoglycemia.
Bone Marrow Cell Isolation
The protocol of bone marrow cell isolation was modified from the Soleimani and Nadri (22) method. Under general anesthesia with 2% isoflurane, hind limb extirpations were performed at the hip, ankle, and ankle joint. Muscle and connective tissue were dissected away from the femur and tibia. They were divided by cutting the knee joint and the top and end of the bones. A 30-gauge needle attached to a 1-mL syringe was inserted into the bone. Bone marrow was flushed by injection of Hank's balanced salt solution before its collection. After a single wash, bone marrow was dispersed by incubation with 0.05% trypsin/0.53 mM ethylenediaminetetraacetic acid solution (Mediatech Inc., Manassas, VA).
Islet and Bone Marrow Cell Transplantation
Cell transplantation was performed under the left kidney capsule. Recipients were divided into four groups: (1) islet group (200 syngeneic islets: nϭ12), (2) bone marrow group (1-5ϫ10 6 syngeneic bone marrow cells: nϭ11), (3) isletϩbone marrow group (200 syngeneic islets and 1-5ϫ10 6 syngeneic bone marrow cells: nϭ13), and (4) sham group (skin and renal capsule incisions with no transplantation: nϭ5).
Islet Function Tests
Blood glucose was measured at postoperative days (PODs) 0, 1, 2, 3, 5, 7, 10, 14, 17, 21, 24, and 28. Blood samples for serum insulin were acquired at PODs 0, 3, 7, 14, and 28. Glucose tolerance test (GTT) was measured at PODs 7, 14, and 28. Days to, and the percentage of animals achieving, normoglycemia were calculated. In this study, normoglycemia was defined as a blood glucose level of Յ11 mmol/L. Intraperitoneal GTTs were performed by overnight fasting for 10 hr and then injecting mice with 2.0 g/kg body weight of glucose solution followed by tail vein blood samples at 0, 15, 30, 60, 90, and 120 min after injection. Blood glucose levels were measured by Accu-Chek Aviva glucose monitors, and serum insulin was measured using a rat/mouse insulin enzyme-linked immunosorbent assay kit (Linco, MO). In another group of mice, blood glucose, serum insulin, and GTT were evaluated for up to 3 months to test the long-term effects of bone marrow cell cotransplantation.
Histologic Assessment
Kidney and pancreatic specimens were acquired from three or more mice at PODs 3, 7, 14, 28, and 84, and photographs of the fresh organs were obtained to assess the density of new vessels around islets/bone marrow. Tissue was then fixed with 10% formalin, embedded in paraffin and cut into 5 m sections. Specimens were stained with hematoxylin and eosin to identify cellular changes. Immunohistochemical staining was performed for insulin to identify islets, cluster of differentiation (CD) 34 to detect bone marrow cells, VEGF for angiogenesis, PDX-1 for regeneration of insulin producing cells, and von Willebrand Factor (vWF) for newly formed blood vessels. For vWF and PDX-1 staining, specimens were treated with proteinase K (Dako, Carpenteria, CA). Primary antibodies were guinea pig anti-insulin antibody (Dako, Carpenteria, CA) diluted 1:100, rabbit anti-CD34 (Santa Cruz Biotechnology Inc., Santa Cruz, CA) diluted 1:100, goat anti-VEGF (p-20) (Santa Cruz Biotechnology Inc.) diluted 1:50, rabbit anti-vWF (Abcam, Cambridge, MA) diluted 1:2000, and goat anti-PDX-1 (Santa Cruz Biotechnology Inc.) diluted 1:100. After incubating with biotinylated secondary immunoglobulin (Ig)-G antibody (Vector Laboratories, Burlingame, CA, and Santa Cruz Inc.), a peroxidase substrate solution containing 3,3Ј-diaminobenzidine (Brown, Dako) or aminoethylcarbazol (AEC)ϩ (Red for insulin, Dako) was used for visualization and counterstained with hematoxylin (23) . Alexa Fluor 488 goat anti-rabbit IgG (identifying insulin and CD34) and Alexa Fluor 568 rabbit anti-goat IgG (identifying VEGF and PDX-1) were used for fluorescent staining. Apoptosis was detected by the TdT-mediated deoxyuridine triphosphate (dUTP)-biotin nick end labeling (TUNEL) method using an in situ apoptosis detection kit (Promega, Madison, WI). Sections were treated with proteinase K and incubated with TdT enzyme for 60 min at 37°C. After washing in phosphate-buffered saline, the sections were further incubated with streptavidin horseradish peroxidase solution and visualized with 3,3Ј-diaminobenzidine (20) .
The percentage of VEGF expression in islets (insulinpositive areas) or bone marrow cells (CD34-positive areas) was assessed as follows: VEGF-positive area (in red) divided by insulin or CD34-positive area (in green) multiplied by 100 (%). Islet apoptosis was expressed as a percentage of TUNELpositive islets relative to total islets (TUNEL-positive cells)/(total islet cells)ϫ100 (%). vWF-positive vessel numbers were calculated from vWF-positive lumens at the transplant site.
Pancreatic specimens were collected for counting residual native islets and evaluating PDX-1-positive areas in islet, and ␤-cell regeneration was compared in all treatment groups at POD 28 (islet transplants, bone marrow transplants, and isletϩbone marrow transplants). Image analyses were performed using image analysis software (Image J ver. 1.40, NIH, USA).
Statistical Analysis
Data are expressed as meanϮstandard error of the mean. Statistical analyses were performed using JMP 5.0.1J for Macintosh (SAS Institute Inc., Cary, NC). Dunnet test or analysis of variance was performed for statistical analysis of all results except the percentage of normoglycemia, which was performed by the Kaplan-Meyer method and log-rank testing. Significance was designated at PϽ0.05.
RESULTS
Blood Glucose, Serum Insulin, and GTT
Blood glucose levels were lowest in the isletϩbone marrow group and significantly lower than the bone marrow (PϽ0.0001) and sham groups (PϽ0.003) (Fig. 1A) . The per-FIGURE 3. Photomicrographs of fresh kidneys recovered from islet, bone marrow, and isletϩ bone marrow group mice at POD 3, 7, 14, 28, and 84. Although new vessels could not be detected in any groups at POD 3, we saw newly formed vessels (arrows) in and around the transplant site (outline) in bone marrow and isletϩbone marrow groups at POD 7 and more prominently at POD 14. Mature vasculature was seen at PODs 28 and 84.
centage of animals reaching normoglycemia was higher in the isletϩbone marrow group than in the islet alone group (46.2%, 6/13 vs. 25%, 3/12, Pϭ0.32, Fig. 1B ). There was no significant difference between the two groups in the time to normoglycemia (3.7Ϯ0.5 days for islet alone vs. 5.8Ϯ1.7 days for isletϩbone marrow, Fig. 1B ). There were no normoglycemic mice in the bone marrow only or sham groups. Serum insulin was significantly higher in the isletϩbone marrow group compared with the islet alone group at POD 28 (PϽ0.05, Fig. 1C ). Serum insulin was higher in the isletϩbone marrow group compared with bone marrow only and sham groups at all time points (Fig. 1C) . Glucose tolerance in both the islet alone and the isletϩbone marrow groups was significantly improved relative to the bone marrow alone and sham groups at POD 7 (Pϭ0.03 both, Fig. 1D ). Interestingly, glucose tolerance appeared better in the bone marrow alone group than the other groups at PODs 14 and 28 (Fig. 1E, F) .
In long-term observations (up to 3 months), the isletϩbone marrow group had lower blood glucose than the islet alone group (Pϭ0.06), and this trend became significant at PODs 63 to 84 (PϽ0.05, Fig. 2A ). Serum insulin was higher and the GTT AUC was lower in the isletϩbone marrow group compared with the islet alone group, though the difference was not significant (Fig. 2B, C) . In summary, islets cotransplanted with bone marrow cells had improved function compared with islet alone transplants in diabetic recipients.
Angiogenesis Observed With Transplantation of Bone Marrow Cells
Photographs of the excised kidney at POD 3 revealed no evidence of neovascularization in or around the transplant sites in any of the experimental groups (Fig. 3) . At POD 7, newly formed vessels were observed in the bone marrow alone and the isletϩbone marrow groups (Fig. 3) . At POD 14, angiogenesis appeared more prominent in bone marrow alone and isletϩbone marrow groups relative to the islet alone group (Fig. 3) . At days 28 and 84, mature vasculature was observed in the bone marrow and isletϩbone marrow groups.
Histologic analysis revealed significantly more new vessels in bone marrow and isletϩbone marrow groups relative to the islet alone group at PODs 14, 28 and 84 (PϽ0.05, Fig.  4A, B) . The number of new vessels found per transplanted tissue area (mm 2 ) was significantly higher in bone marrow and isletϩbone marrow transplant groups at POD 7 (Fig.  4C) . Vascularization was more prominent in bone marrow (ϩislet) transplantation than in islet alone transplantation. Vessel numbers in the field of view (magnification is 100ϫ) were significantly more in bone marrow and isletϩbone marrow groups compared with the islet group at PODs 14, 28, and 84. (C) Vessel numbers divided by graft area (mm 2 ) were also significantly more in bone marrow and isletϩbone marrow groups at PODs 3 and 7. Statistical analysis was performed by Dunnet test, and significant difference was PϽ0.05.
Assessment of VEGF Expression
VEGF expression within islet tissue was not prominent during the experimental period in both the islet and isletϩbone marrow groups, and there was no significant difference between the two groups (Fig. 5A, B) . However, VEGF expression in bone marrow cells was significantly increased in both bone marrow alone and isletϩbone marrow groups at PODs 14 and 28 compared with the islet alone group (Fig. 5A,  B, PϽ0.05) . These results suggest that enhanced peri-islet angiogenesis in this study was dependent on the presence of bone marrow cells.
Regeneration of ␤ Cells
The expression of PDX-1 was investigated in transplanted bone marrow to monitor the development of islet cell precursors. Although PDX-1 expression was low at PODs 3 and 7 in both bone marrow and isletϩbone marrow groups, it increased by approximately 10% at PODs 14 and 28. There was a significant difference between PODs 3 and 14 in the bone marrow group (3.9%Ϯ2.0% vs. 13.9%Ϯ2.1%, PϽ0.05, Fig. 6A, B) . However, insulin-positive cells were not detectable at any time point up to POD 84.
There was also no significant difference in either the number of residual native pancreatic islets or the number of PDX-1-positive pancreatic islets among experimental groups (islet alone, bone marrow alone, and isletϩbone marrow; see 
Other Histologic Findings
TUNEL staining revealed few or no apoptotic cells within islets throughout this study in both the islet alone and the isletϩbone marrow groups (data not shown).
DISCUSSION
Bone marrow consists of blood cells and precursor cells. MSCs and EPCs derived from bone marrow cells have emerged as useful substrates for neovascularization (8) . Pre- The ratio was significantly higher in VEGF/CD34 (both bone marrow and islet bone marrow groups) than VEGF/insulin in islet group. Statistical analysis was performed by Dunnet test, and significant difference was PϽ0.05.
vious studies revealed that mesenchymal cells have an ability to promote angiogenesis and vascularization by producing some angiogenic factors under hypoxic conditions in vitro (24) , and animal MSC and/or EPC transplantation study models also revealed their effectiveness in promoting angiogenesis and improving local ischemia in ischemic heart disease (25) , cerebral infarction (26, 27) , and leg ischemia (28, 29) models. In this study, syngeneic bone marrow cells were transplanted to evaluate their effect on islet graft function and angiogenesis.
Bone marrow cotransplantation with islets in a type 1 diabetes model yielded the following results in this study: (1) lower blood glucose and elevated serum insulin, (2) an improvement of blood glucose 3 months after transplantation, and (3) more prominent vascularization and expression of VEGF. It appears that bone marrow cells released the angiogenic factor VEGF throughout the posttransplantation period, whereas VEGF released from islets was minimal and decreased over time. The result was continued angiogenesis with bone marrow transplantation. This enhanced vascularization correlated with improved islet function.
The origin of the enhanced vasculature observed with bone marrow cotransplantation and the mechanism by which it develops remain to be elucidated. Labeled animal models, for example, green fluorescent protein (GFP) transgenic mice or congeneic Ly antigen mice, could serve as a useful tool to detect the origin of bone marrow transplant-associated neovasculature. It would also be of value to investigate whether there is a direct contribution of bone marrow cells or an effect mediated by proangiogenic products of bone marrow. Although the purpose of this study was the detection of any effect of bone marrow cotransplantation on islets, further studies are needed to investigate the mechanism of the effects described above.
Previous studies have examined the role of bone marrowderived cells in the regeneration of ␤ cells. It has been reported that MSCs can differentiate into ␤ cells under certain conditions (10) , but other studies have reported low to nonexistent regeneration rates (11, 12) . Some PDX-1-positive cells were detected, but no insulin-positive cells were detected in bone marrow in this study. Additionally, no diabetic mice with bone marrow only transplants had lower blood glucose even up to 3 months after transplantation. Although hyperglycemia may be one of the important triggers for bone marrow cells to differentiate into insulin producing cells, the aforementioned results suggest that hyperglycemia alone is not sufficient to result in complete differentiation of bone marrow precursors into ␤ cells within a 3-month time frame.
As for the lack of detection of islet apoptosis up to POD 84 in either islet or isletϩbone marrow groups, this may be due to the relatively mild hypoxia of aggregated renal subcapsular grafts in comparison with dispersed intrahepatic (intraportal) grafts. The liver is suspected to be a nonideal transplant site as previously evidenced by severe hypoxia and apoptosis at the early stages after transplantation (20, 21, 30) . Therefore, it may be even more effective to cotransplant bone marrow cells intraportally to prevent islet hypoxia.
The beneficial effect of bone marrow cotransplantation with islets may be due to mesenchymal cells. We used whole bone marrow cells and did not isolate and use mesenchymal cells alone, akin to a clinical setting where islet isolation and transplantation is typically an emergency precluding adequate time for mesenchymal cell isolation and pretransplant culture. Bone marrow cells can be acquired from brain-dead donors concomitant with a pancreatectomy allowing cotransplantation with islets from the same donor. However, safety and effectiveness of whole bone marrow cotransplantation with islets need to be verified retrospectively in animal models before clinical translation.
In conclusion, bone marrow transplantation has various potential benefits in the treatment of diabetes (10, (31) (32) (33) (34) (35) . In this study, bone marrow transplantation with islets was associated with enhanced angiogenesis and improved islet function. Cotransplantation of bone marrow should be included among potential therapeutic strategies aiming at improving the outcome of clinical islet transplantation. 
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